56 results about "Tumor biology" patented technology

In order to solve the high-speed cancer excited state problem, a biological retarder is needed. Cancer energy is converted into intramolecular transfer or other vibrational state transfer through collision. By means of the nucleus retarder principle, a neutron and a retarder atomic nucleus are subjected to collision so that the speed can be decreased, and the retarder which does not absorb neutrons and does not react with neutrons is selected. An important task of the cancer biology and even the natural science is that which material can bear a cancer nuclear fission biological retarder. According to repeated experiments, various safety factors are synthesized, and finally a biological moderator is correctly selected through a successful experiment. Bifidobacterium is free of toxicity and harm to a body, and the biological retarder can be ideal for treating a cancer. In the future, more microorganism retarders will be produced, the biological retarder is used for decelerating tumors, a proper amount of deceleration molecular nuclear energy can be used as senile cell addition nuclear energy, and the biological retarder gives power to biological science and will play an indispensable critical role.

The invention belongs to the technical field of medicine, and specifically relates to a primary tumor cell culture medium, culture method and application. The primary tumor cell culture method provided by the invention comprises the steps as follows: preparing a primary cell culture medium which comprises the following components: hydrocortisone, EGF, Insulin, a ROCK inhibitor, but not contains cholera toxin, and is an improvement of the existing primary cell culture medium; culturing tumor tissue epithelial cells on laid-out trophoblast cells by using the primary cell culture medium, and enabling the tumor tissue epithelial cells to proliferate rapidly under the combined action of growth factors secreted by the trophoblast cells and nutrient factors contained in the culture medium; and digesting and sub-culturing the tumor tissue epithelial cells when the tumor tissue epithelial cells grow to a cell density of about 80% to 90%. A convenient primary cell culture method is used to obtain immortalized cells possessing the biological characteristics of a patient's own tumor, and the problem of immortalization of the primary culture of tumor cells is solved, thereby realizing personalized treatment for the patient.

The invention provides a human brain glioma cell line and an establishing method and application thereof. The human brain glioma cell line is preserved in China Center for Typical Culture Collection with an accession number of CCTCC No. C201115. The human brain glioma cell line is established by subjecting brain glioma cells originated from a clinic specimen to primary culture and subculture, can be directly used for in vitro drug screening or generation of human brain glioma in mammals and is used for establishing a human brain glioma animal model and screening candidate drugs used for treating human brain glioma. The human brain glioma cell line has stable properties, can realize stable multiple passages and maintain stable properties even after in vitro passage to the 50th generation; pathogenesis of human brain glioma, drug susceptibility, transitivity and other related characteristics can be analyzed in vitro and in vivo, so two correlated in-vitro and in-vivo anti-brain glioma drug screening platforms can be established, and novel experimental materials closer to clinic oncobiological characteristics are provided for research on human brain glioma.

A tumor molecular typing prediction system comprises a gene expression data extraction module, a missing value preprocessor, an important gene extraction module and a US-ELM (Extreme Learning Machine) molecular typing module, wherein the gene expression data extraction module is used for obtaining tumor gene expression data; the missing value preprocessor is used for filling the obtained tumor gene expression data with missing values; the important gene extraction module is used for extracting important tumor genes determining survival time from the tumor gene expression data; the US-ELM molecular typing module is used for performing tumor molecular typing prediction on the important tumor genes by adopting US-ELM. The tumor molecular typing prediction system overcomes the defects of slow speed, poor generalization performance and low classification accuracy of conventional tumor molecular typing techniques, realizes tumor molecular typing prediction which is rapid and high in classification accuracy, and can perform unsupervised machine learning on multiple types of tumors. By the application of the system in tumor molecular typing prediction, biological behaviors of the tumors can be better judged, and the direct purpose of the system is to provide the reference base for formulation of personalized treatment programs instead of obtaining a diagnosis result.

A variety of genetic constructs are disclosed that will find both in vitro and in vivo use in the area of tumor biology and cancer therapy. In particular, expression constructs are provided that contain a p16 encoding region and other regulatory elements necessary for the expression of a p16 transcript. One version of the expression construct is a replication-deficient adenoviral vector. Also provided are methods for the transformation of cell lines and the inhibition of cancer cell proliferation.

The invention discloses a human lung adenocarcinoma cell line and an application thereof. The human lung adenocarcinoma cell line is preserved at China Center for Type Culture Collection (CCTCC) on May 23th, 2014, in Wuhan University 430072, China. The name of a culture is human lung adenocarcinoma cell ZRLC-1; and a preservation number is CCTCC NO: C2014103. The human lung adenocarcinoma cell ZRLC-1 can be used as an experimental material in lung adenocarcinoma basic and clinical research, and can be used for establishing an animal model for occurrence, development and metastasis of lung cancers. The human lung adenocarcinoma cell line has stable characters, can be sub-cultured for a plurality of times stably, and can highly express epithelial markers such as EpCAM and E-cadherin. Flow cytometric analysis shows that EpCAM positive cells reach over 99.70%; and novel experiment material closer to the biological characteristics of clinical tumors are provided for the research of the lung cancers.

The invention provides a PET/CT (Positron Emission Tomography/Computed Tomography) macroscopical digital information and pathological microscopic information matching method. A postoperative sample is reduced into an in-vivo state and is soaked into formalin; a cross section is formed between the tracer highest-ingestion layer surface in a PET/CT image and an adjacent anatomic landmark; the sample is cut apart from the middle in the cross section direction, and is soaked into the formalin; HE (Hematoxylin-Eosin) staining pathological sections are manufactured; a paraffin block region of an immune tissue chemical staining region in each HE staining pathological section is determined; the selected paraffin block region is fixed, and the paraffin section cutting is performed; and the parameter of the tracer high-ingestion layer surface in each layer of PET/CT image and the corresponding layer immunohistochemistry expression are analyzed. The PET/CT image information and immunohistochemistry information matching accuracy is improved; a tracer high-ingestion region and a histology region are accurately registered; and after the matching, the accuracy of the PET/CT on the detection of the in-vivo oncobiology information can be verified.

The invention relates to a detection method for metastatic osteosarcoma molecular targets, a gene combination and a kit. The method has the advantages as follows: the research firstly finds that 1) for the metastatic osteosarcoma, the extracellular vesica based whole transcriptome sequencing finds a molecular characteristic spectrum obviously related to metastasis and has the advantages of noninvasive property, dynamic tracking, and the like, and 2) abundant tumor bio-markers are gathered in the extracellular vesica of metastatic osteosarcoma, and the method has a significance in clinically assessing tumor metastasis and detecting drug targets. The invention designs the gene combination containing 158 genes. According to the gene combination, the driving genes and target genes related to the osteosarcoma pulmonary metastasis can be dynamically monitored after the purification for the blood exosome of the clinic patient and the RNA extraction.

The invention discloses a human thymoma cell line and application thereof, belonging to the field of tumor biology. The human thymoma cell line is named Thy0517 and has a collection number of CGMCC (China General Microbiological Culture Collection Center) No.9328. The human thymoma cell line Thy0517 has main advantages of having protein expression similar to primary tumor tissues, abnormal karyotype and characteristics of tumor cells with in-vitro tumor forming capability. After in-vitro continuous passage culture, the characteristics of thymoma cells keep unchanged, and therefore the human thymoma cell line can be used as a cell material for researching and developing thymoma-related drugs. EGFR (Epidermal Growth Factor Receptor) expression of the human thymoma cell line is positive, so that proliferation, angiogenesis, adhesion, invasion and metastasis of the tumor cells can be promoted; the cell line can be used as a powerful cell tool for researching EGFR-targeted drugs.

The invention discloses a method used for discovering and identifying liver cancer serum differential expression proteins and verifying marker proteins. According to the method, iTRAQ labeling MALDI-TOF MS/MS technology is adopted for discovering and identifying liver cancer serum differential expression proteins and MRM verifying of marker proteins. According to the method, searching on effectivetumor markers possesses important meaning on canceration mechanism study, disease early stage diagnosis, and prognosis. Selected novel liver cancer protein markers are subjected to in vivo and in vitro experiments such as gene knockin and knockout, and nude mice transplanted cancer, influences of blocking or up-regulating of expression of candidate genes on tumor biological behavior are observed,and key proteins capable of influencing human liver cancer occurrence and development are positioned, the effects of the key proteins in a system signal network is analyzed based on bioinformatics analysis, and the feasibility, the liver cancer diagnosis value, and the clinical significance of the key proteins in clinical applications including liver cancer prevention, early stage diagnosis, andprognosis is evaluated based on MRM absolute quantitative verification.

The invention discloses a bacterium AD05 which is separated from a human intestinal tract and can generate anti-cancer active metabolites and application of the bacterium AD05. Feces of healthy persons is used as a sample and is screened by the aid of first Gauserime solid culture media with potassium dichromate, so that the bacterium which can generate the anti-cancer active metabolites can be ultimately separated from the human intestinal tract and is named as AD05. The bacterium AD05 and the application have the advantages that the bacterium AD05 has the closest genetic relationship with Fimbriimonas ginsengisoli Gsoil 348 as discovered in 16S rRNA (ribosomal ribonucleic acid) comparison, and obvious anti-tumor activity of the bacterium AD05 and the metabolites of the bacterium AD05 is sufficiently proved by experiments; the bacterium is sourced from the human intestinal tract and accordingly has little or zero side effects for human bodies; a novel technical means is provided for tumor therapy, and important effects can be realized for development of biological tumor therapy.

The invention relates to animal models for in vivo screening biological macromolecules having influences on tumor cell biology, in particular to genes or protein which have influences on tumor angiogenesis. It cannot be proved that the genes or protein have the influences on functions of the tumor cell biology through in-vivo experiments, but an interference factor that new blood vessels affect the growth of tumors can be effectively shielded by using the models. According to the animal models for in vivo screening the biological macromolecules having the influences on the tumor cell biology, the reliable models are provided for studying the further functions of the biological macromolecules on an angiogenic factor and an inhibiting factor of the existing tumor vessels, a foundation is provided for the clinical application of the models, and the models are of great significance.

The invention discloses human glioma primary cells and an in-vitro isolation and culture method and an application thereof. The cells are named as a low-grade human glioma primary cell XHLG-07 and a high-grade human glioma primary cell XHHG-02 and have the preservation numbers of CCTCC NO:C2018256 and CCTCC NO:C2018215 respectively. The isolation and culture method comprises the steps: acquiring aglioma tissue excised after operation in clinic in vitro, removing blood vessels in the tissue and an adipose tissue by anatomical tweezers, digesting by collagenase/pancreatin, filtering, carrying out low-speed centrifugation to obtain a cell precipitate, carrying out lysis of erythrocytes with an erythrocyte lysis solution, resuspending cells in a DF31 complete culture medium and carrying out inoculation culture. The isolation method can be used for acquiring WHO glioma primary cells with different grades. The obtained cells can be used for analyzing pathogenesis, drug sensitivity and metastasis of human brain gliomas with different grades in vitro and in vivo, and provide research materials more similar to the biological characteristics of clinical tumors for the study of human brain gliomas with different grades.

The invention discloses a human esophageal squamous carcinoma cell line NCCE1 as well as an establishment method and application thereof. The esophageal cancer cell line disclosed by the invention ispreserved in China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: C2020166. The human esophageal squamous carcinoma cell line established by the invention is stable in character, can be stably subcultured, and can induce subcutaneous tumor formation of mice. As a cell and animal model, the model can be directly applied to research and development of anti-cancer drugs and diagnostic reagents, and provides a new experimental material closer to clinical tumor biological characteristics for esophageal squamous cell carcinoma research.

The invention discloses establishment of a diagnostic model for liver cancer and normal human and a diagnostic model for liver cancer and chronic liver disease. An SELDI-TOF-MS technology is used, thediagnostic model for liver cancer and normal human and the diagnostic model for liver cancer and chronic liver disease are established; sera of 48 cases of patients with liver cancer, 17 cases of patients with chronic liver disease and 33 cases of healthy people are collected; the SELDI-TOF technology is used for detecting the samples; searching of effective tumor markers for researches of canceration mechanism and early diagnosis and prognosis judgment of diseases is of great significance. The effects of blocking or up-regulation of expression of candidate genes on tumor biological behaviorsare observed, and key proteins affecting generation and development of human liver cancer are positioned; through bioinformatics analysis, the role of the key proteins in a system signal network is analyzed; through MRM absolute quantification verification, the value of liver cancer diagnosis of liver cancer key protein polypeptides is evaluated and the clinical relevance is analyzed, and the feasibility of the key proteins in clinical applications, such as prevention, early diagnosis and prognosis of liver cancer, is provided.

The invention discloses a human pituitary adenoma cell line and application thereof, and belongs to the field of tumor biology. The collection number of human pituitary adenoma cell line (HPA1446) is CGMCC NO.12672. The human pituitary adenoma cell line has the advantages that the cell line can be cultured in vitro for a long time, the cell characteristic is not changed, and the cell line is a powerful tool for related research of pituitary adenoma; the cell line is a powerful tool for studying tumor disease and related molecule action mechanisms, preparing tumor related animal experiment models, studying, screening and evaluating tumor treatment medicines/methods/diagnosis reagents, developing tumor medicine targets and tumor biological treatment new techniques, and detecting study of related biological engineering.

The invention discloses a human gastric cancer cell line with 5-fluorouracil resistance and an establishing method and application thereof. The human gastric cancer cell line is preserved in China Center for Type Culture Collection and has a preservation number of CCTCC NO:2013154. The human gastric cancer cell line has the advantages of stable characters, stable multiple passages, high tumor formation rate, short incubation period and good uniformity, and provides a novel experimental material closer to the biological characteristics of clinical tumor for the study of gastric carcinoma. The human gastric cancer cell line has tumorigenicity; the generated tumor has 5-fluorouracil resistance and can be used to analyze the in vitro and in vivo drug sensitivity and resistance correlation, and then establish in vitro and in vivo two related drug screening platforms; and the is cell line is ideal for basic research of gastric cancer and clinical early stage application.

The invention discloses an FGF19 over-expression human liver cancer cell line and application thereof. The GF19 over-expression human liver cancer cell line is preserved in China Center for Type Culture Collection with the preservation number of CCTCC NO:C201663. The above human liver cancer cell has stable properties, can be stably repeatedly passaged, has a high tumorigenesis rate, a short incubation period and a good homogeneity, and provides a new experimental material close to the biological characteristics of clinical tumor for liver cancer researches. The human liver cancer cell line has a tumorigenesis ability after being inoculated into nude mouse bodies; and compared with passage parental tumors, the human liver cancer cell line can be used to analyze the drug sensitivity in vitro and in vivo in order to establish a drug screening platform, and is an ideal cell for the basic research and the preclinical application of the human liver cancer.

The invention provides a preparation method of an RBM5 FISH probe for lung cancer detection. The RBM5 FISH probe can be applied to early diagnosis of lung cancer, can significantly improve the diagnosis accuracy when combined with an existing molecular probe, is applicable to multiple types of detection samples, such as paraffin sections, cell drops, cell smears and sputum cells, and can be applied to detection of various clinical samples. A kit can be prepared from the RBM5 FISH probe, the RBM5 FISH probe can be applied to fields of tumor biology, cytogenetics and the like, and comprehensive assessment on relations between various molecular markers and development of the lung cancer is facilitated.

The invention relates to the technical field of medication. The tumour is always cured by operation, irradiation and chemical medication, and the induction differentiation therapy of malignant tumour becomes the research hotpot and frontier field of cancer biology and tumor therapeutics at present. The invention aims at providing a now application of tunicamycin which is the application in preparing a tumour cell reversing drug. The concentration of low-dosage tunicamycin adopted by the invention is 0.1-0.5mug/ml. After a myeloma cell line is treated, myeloma cell strain is differentiated in state, which is shown as cells are transited into mature plasma cell state; cell differentiation antigen CD49e is raised; and excreted immune globulin light chains are also increased. The invention has the advantages of low drug dosage of the tunicamycin, exact effect, less influence on normal cell and benefit for improving the living state of tumour patients.

The invention discloses an organizing micro array chip which comprises sheet bases and organizing points, wherein the organizing points are arranged and attached on the sheet bases by girding type; the organizing points are arranged in line by one or some biology and behavior character.

The invention discloses a free-type HPV18-containing cervical epithelia interior tumor-like lesion cell line and application thereof. A clinic sample from the cell line is 1-2 cm<3> of a cervical epithelia interior tumor-like lesion clinic tissue sample of a HPV18 infected patient, no other treatment is adopted, after in-vitro direct culture, in-vitro stable passage is performed, on the basis of PCR and rolling circle amplification experiments, it is authenticated as a free-type HPV18-containing Chinese woman cervical epithelia interior tumor-like lesion cell named as a cervical epithelia interior tumor-like lesion cell HCINC/HL-017 preserved at CCTCC, and the preservation number is CCTCC NO:C2015124. The cell line can have the application prospect at the aspect of HPV18 virus biology, HPV18 infected cervical cancer tumor biology, and anti-HPV and anti-cervical-cancer drug and vaccine development.

The invention provides a prostatic cancer marker and a therapeutic drug thereof, and belongs to the technical field of tumor biology. By detecting the difference of the expression quantity of Lnc-RP5-952N 6.1 in prostatic cancer tissue and para-carcinoma tissue, the result shows that Lnc-RP5-952N 6.1 is highly expressed in the prostatic cancer tissue, the expression difference of Lnc-RP5-952N 6.1 in the prostatic cancer tissue and para-carcinoma tissue has excellent specificity and sensitivity, and therefore Lnc-RP5-952N 6.1 can serve as the marker of prostatic cancer and is used for assisting in diagnosis of prostatic cancer.

The invention discloses a carrier for expressing target genes at high efficiency and high specificity in tumor cells, which is an annular carrier with the sequence shown as SEQ ID NO. 1. The carrier T-VISA can express the target genes at high efficiency and high specificity in the tumor cells, the expression effect is the same as that of a cytomegalovirus (CMV) promoter, and the carrier T-VISA has the characteristic that the expression in normal tissue cells is very low. Therefore, the carrier T-VISA provided by the invention has wide application values that: 1, the carrier T-VISA can be used for driving any target genes to express at high efficiency and high specificity in the tumor cells, including gene reporting such as luciferase and green fluorescent protein (GFP) and gene treatment genes such as p53 (cell apoptosis protein genes), IL-2 (immune regulation protein genes) and the like; and 2, the carrier T-VISA can be used for the study and the application of tumor biology, tumor signal conduction, tumor gene regulation and control and gene treatment after being combined with corresponding target genes.

The invention belongs to the technical field of tumor biology and discloses a method for preparing a bromocriptine drug-resistant cell strain for rat prolactinoma. Rat prolactinoma MMQ cells are takenas parent cells, the drug administration process inside the human body is simulated through bromocriptine, and the bromocriptine drug-resistant cell strain MMQ/BRC for rat prolactinoma is establishedand acquired through induction with a method of repeated large-dose impact and gradual drug concentration increase. The bromocriptine drug-resistant cell strain for rat prolactinoma, which is prepared with the method, has the advantage of stable drug resistance, can be used for researching the characteristics of the morphology and biology of bromocriptine drug-resistant cells of human prolactinoma, researching the tumor drug resistant mechanism and analyzing the sensitivity of anti-tumor drugs and screening and evaluating anti-tumor drugs, can also be used for preparing a drug-resistant reversal agent or drug for tumor and has higher scientific research and production application value.

The invention provides a human small cell lung cancer cell strain with combined drug resistance to etoposide and carboplatin as well as a preparation method and application thereof, wherein the human small cell lung cancer cell strain is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC No: C202168. The small cell lung cancer cell strain is stable in character, can be stably passed for multiple times, and can be used for generating human small cell lung cancer in mammals and preparing a human small cell lung cancer model; the cell is tolerant to combined medicine of etoposide and carboplatin which are first-line treatment medicines for small cell lung cancer, and can be used for researching a drug-resistant molecular mechanism of small cell lung cancer and candidating the drugs for treating drug-resistant human small cell lung cancer are screened. According to the invention, a new experimental material closer to clinical tumor biological characteristics is provided for small cell lung cancer research.